Marshall Wace, LLP Clene Inc. Transaction History
Marshall Wace, LLP
- $77.3 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding CLNN
# of Institutions
6Shares Held
230KCall Options Held
0Put Options Held
25K-
Morgan Jess S & CO Inc112KShares$492,8000.27% of portfolio
-
Black Rock Inc. New York, NY83.5KShares$367,1840.0% of portfolio
-
Pathstone Family Office, LLC Englewood, NJ25.2KShares$111,0120.0% of portfolio
-
Jefferies Group LLC New York, NY4.96KShares$21,8060.0% of portfolio
-
Cutler Group LP3.9KShares$17,1600.0% of portfolio
About Clene Inc.
- Ticker CLNN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 63,502,000
- Market Cap $279M
- Description
- Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral scleros...